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hAortic stenosis (AS) is one of the most common valvular
heart diseases in the developed world and the most
common reason for valve intervention.1 The prevalence
has been estimated to be 12.4% in patients ≥75 years of
age2 and is set to treble by 2050 as a consequence of an
aging population. It is characterized by progressive valve
narrowing and the subsequent left ventricular remodeling
response.3 The only effective treatment for severe AS
remains aortic valve replacement (AVR). Advances in
transcatheter aortic valve replacement (TAVR) have seen
an exponential rise in eligible patients, with approxi-
mately 180,000 patients across the European Union and
North America meeting current criteria.4
The prognosis of symptomatic severe AS is universally
recognized to be poor. Fifty years ago, Braunwald published
his landmark article basedonobservational evidence that still
influences practice today, demonstrating the association
between hallmark symptom—chest pain, dyspnea with
Figure 1
Cardiac magnetic resonance in AS. A, Myocardium without late gadolinium enhancement. B, Partial voluming of the left ventricular outflow tract
(green arrow) and ischemic late gadolinium enhancement (yellow arrow). C and D, Midwall late gadolinium enhancement (red arrows). D, Two
sites of midwall late gadolinium enhancement (red arrows) and partial voluming of the left ventricular outflow tract (green arrow).
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Guidelines strongly recommend AVR after the development
of symptoms or a reduction in ejection fraction in the
absence of symptoms6-8 but rely largely on nonrandomized
data and expert opinion. Symptoms are ideally used as a
marker of incipient left ventricular decompensation prior to
the onset of heart failure or irreversible myocardial injury. In
modern clinical practice, however, the assessment of
symptoms is challenging, particularly in elderly patients
who may be frail, be less mobile, or have multiple
comorbidities. These patients are vastly more common
than 50 years ago. Meanwhile, reduced ejection fraction is
frequently a late finding and often irreversible. Consequent-
ly, there is interest in developing novel, objectivemarkers of
early ventricular decompensation due to progressive
valvular obstruction.
Myocardial fibrosis is the key pathological feature
driving left ventricular decompensation in AS and the
transition from hypertrophy to heart failure.9,10 It can be
divided into diffuse fibrosis, which occurs earlier and is
reversible, and replacement fibrosis, which occurs later
and is irreversible.11 Late gadolinium enhancement (LGE)
on cardiac magnetic resonance (CMR) imaging allows
direct imaging of replacement myocardial fibrosis, which
occurs in a midwall (nonischemic) distribution in AS that
can be clearly differentiated from prior myocardial
infarction (Figure 1). LGE is a powerful predictor of
adverse prognosis in a broad range of myocardial
pathologies, including ischemic and nonischemic cardio-
myopathies and infiltrative disease processes.12-16 LGE is
an independent predictor of mortality in patients with AS
(Figure 2); this has been a consistent finding in multiple
separate cohorts and multicenter studies.17-21 Further-
more, once established, replacement fibrosis progresses
rapidly and does not regress after AVR.11,22 This is of
clinical importance because a proportionate effect on
clinical outcomes has been demonstrated: the more LGE,
the worse the long-term prognosis.21 On the basis ofthese data, there is substantial interest in using midwall
LGE as an early marker of left ventricular decompensation
that can be used to trigger AVR in patients with
asymptomatic severe AS.
Hypothesis
We hypothesize that in asymptomatic patients with
severe AS and midwall LGE, early AVR will improve
outcomes when compared to the current standard of care.
Methods
Study design
Setting. The EVOLVED trial (NCT03094143) is a
parallel-group, multicenter, prospective randomized
open-labeled blinded endpoint controlled trial. Currently,
16 sites in the United Kingdom are recruiting; the
addition of up to 15 further sites is anticipated.
Patient population. The trial will recruit patients
N18 years of age who have severe AS and do not have
symptoms attributable to their valve disease (Figure 3).
Symptoms will be assessed clinically by the attending
physician; this may include exercise stress testing
according to their usual clinical practice. Severe AS will
be determined by the attending physician according to
current guidelines, and the following echocardiographic
criteria will need to be met: aortic valve peak velocity ≥
4.0 m/s, or an aortic valve peak velocity ≥ 3.5 m/s with
an indexed aortic valve areab 0.6 cm2/m2.6,23 Echocar-
diography must be performed within 6 months of the
baseline visit assessment. Minimum echocardiographic
parameters required for eligibility are aortic valve peak
velocity, mean aortic valve gradient, aortic valve area
calculated using the continuity equation, and a qualitative
or quantitative assessment of left ventricular systolic
function. Key exclusion criteria include left ventricular
ejection fraction b50%, concomitant severe aortic or
mitral regurgitation, estimated glomerular filtration rate
Figure 3
Study flowchart. The sample size has been calculated based on an event rate of 25.0% in the routine care arm and 13.4% in the early intervention
arm over the first 2 years; 88 observed primary outcome events will give 90% power at 5% significance level.
Figure 2
Late gadolinium enhancement and all-cause and cardiovascular mortality. Kaplan-Meier curves demonstrating the association between late
gadolinium enhancement on cardiac magnetic resonance and all-cause (A) and cardiovascular (B) mortality in patients with severe AS. Figures
from Musa et al.21
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Table I. Inclusion and exclusion criteria
Inclusion criteria
1. Severe AS
AV Vmax ≥4.0 m/s, or
AV Vmax ≥3.5 m/s + AVA b0.6 cm2/m2
2. No symptoms attributable to AS that warrant AVR
3. N18 years of age
Exclusion criteria
1. Low risk for midwall fibrosis on screening
2. Planned cardiac surgery
3. Previous valve replacement
4. Severe hypertension (SBP N180 or DBP N110 mm Hg)
5. Acute pulmonary edema or cardiogenic shock
6. Left ventricular ejection fraction b50% on CMR
7. Significant abnormalities on CMR that would prevent enrolment
8. Coexistent severe aortic or mitral regurgitation
9. Coexistent mitral stenosis greater than mild in severity
10. Coexistent hypertrophic cardiomyopathy or cardiac amyloidosis
11. Contraindication to CMR
12. Advanced renal impairment (eGFR b30 mL/min/1.73 m2)
13. Pregnancy or breast feeding
14. Judged to be unfit for SAVR/TAVR
15. Patient declines to consider SAVR/TAVR
16. Inability to give informed consent
17. Previous randomization into this study
AS, aortic stenosis; AV Vmax, aortic valve peak velocity; AVA, aortic valve area;
SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated
glomerular filtration rate; SAVR, surgical aortic valve replacement.
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full list of inclusion and exclusion criteria is provided
in Table I.
Clinical assessment and screening. Patients will be
approached and consented for a screening visit where an
electrocardiogram (ECG) will be performed and plasma
high-sensitivity cardiac troponin I (hsTnI) concentrations
measured. Patients will proceed to baseline visit and CMR
if there is ECG evidence of left ventricular hypertrophy
with strain or an hsTnI concentration ≥ 6 ng/L. These
criteria are based on prior observational data demonstrat-
ing the sensitivity and specificity of ECG evidence of left
ventricular hypertrophy and/or strain for the presence of
midwall LGE in patients with AS to be 88% and 67%
respectively, whereas the median hsTnI in AS patients
with midwall LGE was 9.5 ng/L (interquartile range [IQR]
5.7-20.3) versus 4.3 ng/L (IQR 3.3-7.9) in those with-
out.24,25 Any ECG criteria for left ventricular hypertrophy
may be used, including the Peguero–Lo Presti criteria,
Sokolow-Lyon index, and Cornell criteria.26-28 The Abbott
ARCHITECTSTAT troponin I assay (Abbott Laboratories,
Abbott Park, IL) will be used for plasma hsTnI measure-
ment. At sites where access to this assay is not available,
an ECG-only screening pathway will be permitted.24
Other data collected at the screening visit will include
relevant medical history, height and weight, blood
pressure, New York Heart Association (NYHA) functional
classification, Edmonton Frail Scale,29 and World Health
Organization Disability Assessment Schedule 2.0 (WHO-
DAS).30 In addition to hsTnI, further optional phlebotomywill be performed and the sample spun and frozen below −
70°C for future analysis. Explicit consent will be sought for
these samples. Patients will also be consented at the
screening visit for future data linkage analysis, regardless of
whether they fulfill criteria to proceed to CMR.
Cardiac magnetic resonance imaging. For CMR
imaging, either a 1.5- or 3-T scanner may be used
according to local availability. A standardized protocol
will be applied (Figure 4), incorporating routine localizer
sequences, left ventricular 2-, 3-, and 4-chamber cine
imaging and a left ventricular short axis stack (8-mm
slices, no gap). Native T1 measurements may be
performed at the discretion of each site using the
modified Look-Locker inversion recovery sequence.31 A
gadolinium-based contrast medium will then be adminis-
tered according to local protocol; the preferred agent and
dose are 0.15 mmol/kg gadobutrol. This will be followed
by left ventricular outflow tract imaging and fast low
angle shot sequences of the aortic valve in short axis. LGE
imaging will begin 7 minutes after contrast administra-
tion and be performed using either gradient echo or
phase-sensitive inversion recovery techniques, according
to local practice, with a phase swap short-axis stack also
acquired to help exclude artifact. Finally, postcontrast T1
measurements may be performed approximately 20 mi-
nutes after gadolinium administration. Other CMR
imaging sequences of interest may also be added to the
protocol where available. The images will be anonymized
and uploaded to the secure EVOLVED server hosted by
the University of Edinburgh for central core analysis.
The core laboratory is based at the Edinburgh Imaging
Facility, Queen's Medical Research Institute, University of
Edinburgh. Image analysis will be performed using cvi42
for Cardiac MRI (Circle Cardiovascular Imaging, Calgary,
Alberta, Canada). Qualitative assessment of LGE will be
undertaken visually; the presence or absence of a midwall
pattern of LGE will be reported as a dichotomous finding
for the purposes of randomization. Quantification of LGE
will not be undertaken as part of primary image analysis.
The presence of LGE in an ischemic pattern will be
documented during image analysis, but only midwall LGE
will qualify participants for randomization. In the
presence of an ambiguous distribution of LGE, other
findings such as regional wall motion abnormalities,
segmental distribution, and myocardial thinning will be
used to aid in differentiating midwall from ischemic LGE.
The clinical care team is blinded to cardiac findings from
the CMR, with the exception of any clinically relevant
findings that would prevent enrolment or influence
patient management. Such findings include, but are not
limited to, left ventricular ejection fraction b50%,
intracardiac thrombus, or malignancy.
Randomization and blinding. Following completion
of baseline assessments, CMR imaging, and central CMR
review, patients that meet inclusion and exclusion
criteria will be enrolled into the study. A Web-based
Figure 4
Cardiac magnetic resonance protocol. The EVOLVED CMR scanning protocol with representative images from different sequences. * The preferred
gadolinium-based contrast agent and dose are gadobutrol 0.15 mmol/kg. ^ Pre- and postcontrast T1 imaging is optional. LV, left ventricular;
4C, 4-chamber; 3C, 3-chamber; 2C, 2-chamber; SAX, short axis; MOLLI, modified Look-Locker inversion recovery; GRE, gradient echo;
PSIR, phase sensitive inversion recovery.
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To maintain blinding, there are 2 separate randomiza-
tions: one for patients with midwall fibrosis (randomiza-
tion 1) and another for those without midwall fibrosis
(randomization 2) (Figure 3). The 2 randomizations are
critical and result in a pooled group of patients with and
without midwall fibrosis who are allocated to routine
care (group B/C), thus maintaining blinding in the control
group (group B). This will ensure that the CMR result in
the routine care group does not influence symptoms or
decisions regarding timing of AVR.
For randomization 1, patients are randomized in a 1:1
ratio to either early intervention (group A) or routine
clinical care (group B). Minimization techniques will be
used to ensure balancing of key variables: age, sex, aortic
valve peak velocity, ischemic heart disease, and screening
method (ECGand hsTnI or ECGonly). For randomization 2,
patients will be randomized using a flexible adaptive ratio
to either routine clinical care (group C) or no further study
follow-up (group D). The aim of the randomization ratio,
which will be undertaken by the Clinical Trials Unit, is to
balance the number of participants in group C and group B.
Details of the randomization ratio value and the dates of any
change in the ratio will be recorded. No minimization
criteria will be applied to this randomization because the
primary analysis does not involve group C.Patients who are randomized to early AVR (group A)
will be referred immediately following randomization.
The usual local clinical pathway will be followed;
decisions such as revascularization and AVR modality
(surgical or transcatheter) will be made according to the
local heart valve team on a per patient basis. The
intervention should be performed as soon as possible as
an elective procedure and ideally within 2 months of
randomization.
Follow-up for groups A, B, and C will be identical,
which will maintain blinding for patients undergoing
routine care (groups B and C). Patients will be telephoned
annually to assess symptoms and events. NYHA function-
al class and WHODAS 2.0 will be assessed. Medical
records will also be reviewed annually to assess for any
events. Postoperative complications occurring within
30 days of surgery will be recorded, irrespective of
treatment group (Supplementary Table I). Patients in
Group D will not undergo any routine study follow-up,
but patient details will be retained for future linkage
analysis.
Funding and contributors. The EVOLVED trial is
funded by a grant from the Sir Jules Thorn Charitable
Trust (15/JTA). The authors are solely responsible for the
design and conduct of this study, all study analyses, the
drafting and editing of the paper, and its final contents.
Table II. Study endpoints
Primary endpoint
Composite of all-cause mortality or unplanned AS-related hospitalization between randomization and final follow-up visit for study participants with
midwall fibrosis.
Secondary endpoints
1. Mortality (all-cause, cardiovascular, AS related, and sudden cardiac death) between randomization and final follow-up visit.
2. Unplanned AS-related hospitalization between randomization and final follow-up visit.
3. Health and disability as assessed by the 12-item WHODAS 2.0 at the final follow-up visit.
4. The development of left ventricular systolic dysfunction (ejection fraction b45% quantitatively or at least moderate left ventricular systolic dysfunction
qualitatively) between randomization and final follow-up visit.
5. Symptomatic status as assessed by NYHA functional classification at the final follow-up visit.
6. Permanent pacemaker insertion, cardiac resynchronization therapy, or automated implantable cardioverter/defibrillator between randomization and
final follow-up visit.
7. Stroke between randomization and follow-up visit.
8. Endocarditis between randomization and final follow-up visit.
9. 30-d postoperative complications following aortic valve intervention
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The primary endpoint is a composite endpoint of all-
cause mortality and unplanned AS-related hospitalization
between randomization and final follow-up visit for study
participants with midwall fibrosis (groups A and B).
Unplanned AS-related hospitalization is defined as an
unplanned hospital admission with syncope, heart
failure, chest pain, or arrhythmia (ventricular arrhythmia
or second- or third-degree heart block) attributed to AS.
This endpoint will be independently adjudicated by 2
investigators blinded to the details of randomization. AS-
related hospitalizations occurring in the early interven-
tion arm between randomization and intervention will be
included in the intention-to-treat analysis. A third
independent reviewer will adjudicate any conflicts.
There are a number of prespecified secondary endpoints
(Table II, definitions in Supplementary Table II), includ-
ing all-cause mortality, cardiovascular mortality, and AS-
related mortality which will be analyzed in groups A, B,
and C.
Other data will be collected for exploratory analysis.
These will include assessment of other CMR parameters
such as ejection fraction and T1 mapping (native T1,
extracellular volume fraction, and indexed extracellular
volume), biochemical biomarkers such as brain natriuret-
ic peptide, and genetic analyses to assess for gene
associations with myocardial fibrosis.
Statistical considerations
Sample size. We expect the proportion of primary
outcome events (all-cause mortality or unplanned AS-
related hospitalization) to be 25% in the routine care arm
of the study and 13.4% in the early intervention arm (a
hazard ratio of 2) over 2 years of follow-up.17-19 Using a
log-rank approach, we will need to observe 88 primary
outcome events to give us 90% power at 5% significance
level. We have estimated that we will reach 88 events
when we have recruited 356 participants with midwall
fibrosis (slightly more allowing for a 10% dropout rate)
after a mean follow-up of 2.75 years. However, ifnecessary, the study will continue until the prespecified
number of events has accrued.
For further calculations, we have assumed that our
optimal hsTnI threshold will be ~6 ng/L. This is based
upon our preliminary troponin data to date, which
demonstrated that 62% of patients with an aortic valve
peak velocity ≥4.0 m/s had a troponin ≥6.0 ng/L. Of
these patients, 42% had midwall fibrosis on CMR. On this
basis, we have estimated that we will need to screen
approximately 1,600 patients to identify 1,000 patients
for CMR to recruit our target of 400 patients with midwall
fibrosis.
At the time that the required amount of data for the
primary analysis has accrued (comparing early surgery vs
routine care in patients with midwall fibrosis [groups A
and B)], we should also have 90% power to detect a
difference in the all-cause mortality between patients
with and without midwall fibrosis who do not receive
early surgery (groups B and C) of 29% versus 15% (log-
rank test, P = .05, 2-sided test).
Statistical analyses. The primary outcome is defined
as time to first event of all-cause mortality or unplanned
AS-related hospital admission, and the primary compar-
ison will be between group A and group B. Time to
primary outcome is defined as time from randomization
to primary outcome. Patients withdrawing consent will
have their time to primary outcome censored at the last
contact date. The relationship between intervention and
the primary outcome will be analyzed using Cox
proportional-hazard regression adjusted for the minimi-
zation variables used in the randomization algorithm. The
results will be expressed as a hazard ratio with the
corresponding 95% CIs and 2-sided P value (which will
be considered statistically significant if it is ≤.05). The
individual elements of the composite primary outcome
will be reported separately.
Secondary outcomes will be analyzed using appropriate
methods: Cox proportional-hazards regression for time-
to-event outcomes, logistic regression for binary out-
comes, and linear regression for normally distributed
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Continuous outcomes that are not normally distributed
will be analyzed using appropriate nonparametric tech-
niques. Secondary outcomes will be presented for groups
A, B, and C. A first set of secondary analyses will compare
groups A and B, and a second set of secondary analyses
will compare groups B and C.
For the purpose of analysis, we will retain partici-
pants in the treatment groups to which they were
originally assigned irrespective of the treatment
actually received. Every effort will be made to minimize
missing data. Analysis will be a complete case analysis. If
there is a sufficient level of missing data to affect our
conclusions, a multiple imputation analysis will be
undertaken, using clinically appropriate variables, as
a sensitivity analysis. A full statistical analysis plan will
be written during the trial and finalized prior to
database lock.
Ethical considerations
The study protocol will be approved by each region
and will be conducted in accordance with the principles
of Good Clinical Practice. The trial received a favorable
ethical opinion from the South East Scotland Research
Ethics Committee on 12 May 2017 (REC 17/SS/0052).
A trial steering committee will oversee the study. The
former will have final responsibility for the medical and
scientific conduct of the trial, while all staff must comply
with the requirements of the UK Data Protection Act
2018 and the EU General Data Protection Regulation
2018. The principal investigators are responsible for the
overall conduct of the study at each site. The chief
investigator and trial manager are based at the Centre for
Cardiovascular Science, University of Edinburgh.
Participants will be provided with oral and written
information. Participants must have at least 24 hours to
consider the written information before written informed
consent for themain trial can be sought. Patients are free to
withdraw at any stage of the trial. Any data collected until
this point will be retained and analyzed unless the
participant specifically withdraws consent for this. Docu-
mentation and review of any adverse events or adverse
reactions that occur are the responsibility of site investiga-
tors. Only serious adverse reactions or suspected unex-
pected serious adverse reactions related to gadolinium-
based contrast medium administration are required to be
reported to the sponsor. Such an event should be reported
within 24 hours.
Current status
The main site opened on 21 July 2017, and the first
patient was recruited on 16 October 2017. Subsequently,
16 other sites have opened across the United Kingdom.
As of December 2018, a total of 101 patients have
undergone CMR and randomization. We anticipate
opening a further 10-15 sites within the next year.After the first year of recruitment, the number of
patients being screened has been lower than expected.
However, the anticipated prevalence of midwall fibrosis
in patients who have proceeded to CMR has exceeded
the anticipated rate of approximately 40%. Given this, as
well as the new sites yet to open, the trial remains on
course to reach the expected event rate (88 primary
outcome events). Additionally, the reduced number of
CMR scans that are likely to be required, given the
observed prevalence of midwall fibrosis, provides flexi-
bility with resource allocation, with the provision of
extending study follow-up available as a viable option.
Trial registration
The EVOLVED trial is registered at clinicaltrials.gov
(NCT03094143).
Funding
The EVOLVED trial is supported by a grant from the Sir
Jules Thorn Charitable Trust (15/JTA).
Discussion
The optimal timing of aortic valve replacement in
patients with severe AS remains unclear, having never
been investigated in the context of a randomized
controlled trial. Current major international guidelines
support the consideration of intervention in asymptom-
atic patients if there is very severe AS or rapid progression
in valve obstruction, whereas additional weaker recom-
mendations are offered by the European Society of
Cardiology based on severe pulmonary hypertension or
elevated brain natriuretic peptide attributable to AS.6-8
However, long-term outcomes after AVR remain subop-
timal. A growing body of data has identified midwall LGE
to be a powerful independent predictor of poor
prognosis under the current management paradigm.
This has recently been confirmed in a large multicenter
cohort, comprising almost 700 patients (all-cause mortal-
ity 25.2% vs 12.9% at median 3.6 years of follow-up for
patients with and without LGE, respectively).21
EVOLVED will investigate whether the adverse prognosis
observed in these patients can be improved with early
valve intervention.
Myocardial fibrosis is recognized to be the structural
correlate of heart failure and is present in the later stages of
mostmyocardial pathologies.10 In AS, fibrosis appears to be
the central pathological process driving left ventricular
decompensation and the transition from hypertrophy to
heart failure.10 Myocardial fibrosis is therefore a potential
biomarker for early left ventricular decompensation. LGE
on CMR is well suited to the purpose of identifying
replacement fibrosis. The technique can discriminate
between various patterns of fibrosis, differentiating mid-
wall fibrosis due to AS from other forms of myocardial
injury such as myocardial infarction. This is an important
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diastolic dysfunction, or global longitudinal strain. Midwall
LGE has been validated against histology and consistently
demonstrates a close association with other markers of LV
decompensation, including advanced left ventricular
hypertrophy, markers of myocardial injury, reductions in
diastolic and systolic ventricular function, increased
symptomatic status, and reduced exercise capacity.20,32
Moreover, the adverse long-term prognosis associatedwith
midwall LGE has now been confirmed in 5 separate
cohorts.17-21 LGE has therefore been extensively studied
with regard to prognosis; attention is now turned toward
clinical application.
EVOLVED is the first randomized controlled trial to use
midwall LGE as a biomarker of early left ventricular
decompensation and a trigger for AVR in an asymptom-
atic population who does not meet conventional criteria
for intervention. Our hypothesis is that prompt interven-
tion will halt the accumulation of irreversible myocardial
fibrosis—which confers ongoing risk of adverse out-
comes even after AVR—thereby improving long-term
patient prognosis. The primary analysis will compare the
outcomes of patients with midwall LGE randomized to
early intervention (group A) with those randomized to
routine care (group B). Patients in group B will be pooled
with patients who do not have midwall LGE and who are
randomized to routine care (group C) via the second
randomization. This facilitates blinding of patients, study
investigators, and treating physicians to CMR results in
this pooled group. There may be potential bias and
subtraction anxiety in patients allocated to routine care if
CMR results were available; blinding will minimize this.
Furthermore, the study design will allow a comparison of
the natural history of asymptomatic patients with and
without LGE undergoing routine care and also allows for
acquisition of T1 mapping data, an emerging area of
interest in AS.
The use of treadmill exercise testing in AS is
controversial. Although many physicians find it a useful
adjuvant test to help assess a patient's symptomatic status,
the data supporting treadmill testing in patients with AS
are limited, and it has several important limitations in this
patient population. Firstly, impaired mobility may pre-
clude the use of treadmill or bicycle exercise testing in
many AS patients, even if daily activities are not limited.
Secondly, the criteria for determining a positive remain
unclear (all patients will develop dyspnea at some point
during a treadmill test), and symptoms that do develop
may not necessarily be attributable to valvular disease.
Thirdly, exercise testing may extend patients beyond
their usual level of activity; in this scenario, symptoms
elicited do not reflect the reality of symptoms within the
sphere of day-to-day activity. As a consequence, clinical
guidelines do not mandate the use of treadmill testing,
and its use varies widely among practicing clinicians. Our
approach to treadmill testing reflects these clinicalrealities. We have not mandated the use of exercise
treadmill testing as part of our study protocol; however. if
physicians wish to perform a treadmill test to determine a
patient's symptomatic status as part of routine care. they
are free to do so; this will not affect the patient's
eligibility. Ultimately, EVOLVED is envisaged as a
pragmatic randomized controlled trial designed to be
applicable to the broadest range of patients seen in daily
clinical practice.
We have introduced a screening step before CMR to
mitigate the imaging costs of our strategy, both within the
trial and in future clinical practice. Estimation of plasma
hsTnI concentrations now facilitates the detection of
myocardial injury at extremely low levels in a range of
conditions beyond myocardial infarction; consequently,
normal values (approximately b6 ng/L) are a consistent
predictor of patients at low risk of adverse outcome33,34 .
This includes AS, where hsTnI levels are associated not
with markers of coronary artery disease but instead with
the degree of hypertrophy and the presence of myocar-
dial fibrosis.25 As a cheap, widely available, and easily
performed blood test, hsTnI is an ideal screening tool
with which to select patients for CMR. The ECG strain
pattern has been shown to have a high specificity for
myocardial fibrosis in AS24 but may be a suboptimal
screening tool when used in isolation due to low
sensitivity. Therefore, at those sites where the Abbott
hsTnI assay is not available, voltage criteria for LVH (with
or without strain) will be used instead. We expect this
screening approach to reduce the number of CMR scans
in the EVOLVED trial by more than one-third.
Two additional randomized controlled trials in severe
asymptomatic AS are currently under way. A well-
designed but small trial (AVATAR) that aims to recruit
312 patients is under way, initiated in Serbia and
conducted in Europe (NCT02436655).35 This study is
different to EVOLVED with 17 exclusions (including
coronary artery disease and chronic obstructive pulmo-
nary disease). Additionally, all patients must be able to
undergo exercise testing, and coronary angiography is
mandatory; this may limit the generalizability of the
results. The EARLY TAVR trial, randomizing patients with
asymptomatic severe AS to expectant treatment or TAVR,
commenced in July 2017 (NCT03042104). This industry-
sponsored trial (Edwards Lifesciences) will differ
markedly from the current study because it will
not select out patients with LV decompensation and
will mandate a specific valve replacement strategy. The
primary endpoint is freedom from death, stroke, and
unplanned cardiovascular hospitalization.Conclusions
Previous data have demonstrated that irreversible
replacement fibrosis in AS accumulates rapidly once
established and confirmed the poor prognosis associated
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multicenter, blinded, randomized controlled trial to
investigate early AVR compared to routine care in
asymptomatic patients with severe AS and evidence of
myocardial fibrosis on CMR. Our hypothesis is that early
valve intervention will reduce deaths and unplanned
cardiovascular hospitalization in these patients.
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